PFG Investments LLC Purchases 6,164 Shares of GSK plc (NYSE:GSK)

PFG Investments LLC increased its holdings in GSK plc (NYSE:GSK) by 71.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,758 shares of the pharmaceutical company’s stock after acquiring an additional 6,164 shares during the period. PFG Investments LLC’s holdings in GSK were worth $633,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of GSK. JTC Employer Solutions Trustee Ltd lifted its stake in GSK by 71.3% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after purchasing an additional 8,800,822 shares during the last quarter. Hsbc Holdings PLC purchased a new position in GSK in the fourth quarter valued at approximately $92,281,000. Armistice Capital LLC lifted its stake in GSK by 670.5% in the fourth quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock valued at $81,384,000 after purchasing an additional 1,911,000 shares during the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 10.8% in the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock valued at $558,330,000 after purchasing an additional 1,465,165 shares during the last quarter. Finally, Provident Trust Co. lifted its stake in GSK by 53.6% in the fourth quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock valued at $137,746,000 after purchasing an additional 1,297,385 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Morgan Stanley assumed coverage on GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

GSK Price Performance

GSK traded up $0.52 during trading on Monday, reaching $41.63. The stock had a trading volume of 4,241,531 shares, compared to its average volume of 3,448,776. The stock has a market cap of $86.28 billion, a PE ratio of 13.83, a PEG ratio of 1.44 and a beta of 0.64. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. GSK plc has a one year low of $33.33 and a one year high of $43.84. The business has a 50-day moving average of $41.82 and a 200-day moving average of $39.01.

GSK (NYSE:GSK) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. As a group, equities research analysts anticipate that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were paid a dividend of $0.3564 per share. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date was Thursday, February 22nd. GSK’s dividend payout ratio (DPR) is 52.82%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.